Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Beth Israel Deaconess Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07654426CT.gov The CARDIOPROTECT Trial | — | Not Yet Recruiting | — | — | — |
NCT07294677CT.gov CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | — | Recruiting | — | — | — |
NCT07052695CT.gov Mosunetuzumab for CLL MRD Clearance | — | Recruiting | — | — | — |
NCT06692452CT.gov Tazemetostat Plus CHOP in 1L T-cell Lymphoma | — | Withdrawn | — | — | — |
NCT05256641CT.gov Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05495464CT.gov A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05279300CT.gov A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | — | Recruiting | — | — | — |
NCT04980222CT.gov A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04855695CT.gov Avo In R/R And Previously Untreated MCL | — | Recruiting | — | — | — |
NCT04058470CT.gov Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | — | Unknown | — | — | — |
Show 66 more trialsShow fewer
NCT03995147CT.gov Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02889523CT.gov Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | — | Active Not Recruiting | — | — | — |
NCT02589145CT.gov Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | — | Terminated | — | — | — |
NCT02605694CT.gov Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | — | Withdrawn | — | — | — |
NCT02419469CT.gov Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Terminated | — | — | — |
NCT02529852CT.gov A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | — | Completed | — | — | — |
NCT02259010CT.gov A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma | — | Completed | — | — | — |
NCT02214147CT.gov Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function | — | Completed | — | — | — |
NCT01974440CT.gov A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01983969CT.gov Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | — | Completed | — | — | — |
NCT02012088CT.gov Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb | — | Completed | — | — | — |
NCT01855750CT.gov A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT01898078CT.gov Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT01844583CT.gov Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | — | Completed | — | — | — |
NCT01390584CT.gov Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01714947CT.gov Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | — | Completed | — | — | — |
NCT01831505CT.gov Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents | — | Completed | — | — | — |
NCT01512758CT.gov A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT01399372CT.gov Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | — | Completed | — | — | — |
NCT01421173CT.gov Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | — | Completed | — | — | — |
NCT01427114CT.gov R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) | — | Completed | — | — | — |
NCT01327612CT.gov Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | — | Completed | — | — | — |
NCT01276717CT.gov Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
NCT01169532CT.gov Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma | — | Completed | — | — | — |
NCT01222780CT.gov To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | — | Completed | — | — | — |
NCT01120834CT.gov Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT01184885CT.gov A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | — | Completed | — | — | — |
NCT01139359CT.gov Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | — | Withdrawn | — | — | — |
NCT00901069CT.gov Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | — | Completed | — | — | — |
NCT00875056CT.gov Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) | — | Completed | — | — | — |
NCT00770224CT.gov S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00882206CT.gov Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT00896519CT.gov GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT00785798CT.gov Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas | — | Terminated | — | — | — |
NCT00810576CT.gov Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00787527CT.gov SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00771472CT.gov Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) | — | Completed | — | — | — |
NCT00720876CT.gov Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00734890CT.gov Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma | — | Completed | — | — | — |
NCT00791011CT.gov Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | — | Completed | — | — | — |
NCT00561418CT.gov Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma | — | Completed | — | — | — |
NCT00335140CT.gov Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | — | Terminated | — | — | — |
NCT00503594CT.gov Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine | — | Unknown | — | — | — |
NCT00451178CT.gov A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | — | Completed | — | — | — |
NCT00392990CT.gov Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma | — | Completed | — | — | — |
NCT00299182CT.gov Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01527422CT.gov Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL | — | Completed | — | — | — |
NCT00127101CT.gov An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) | — | Terminated | — | — | — |
NCT00133991CT.gov Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia | — | Completed | — | — | — |
NCT00217503CT.gov Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma | — | Completed | — | — | — |
NCT00127140CT.gov A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | — | Completed | — | — | — |
NCT00101101CT.gov Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00450801CT.gov R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00074490CT.gov Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | — | Terminated | — | — | — |
NCT00290433CT.gov Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT00594815CT.gov Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | — | Completed | — | — | — |
NCT00038207CT.gov Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies | — | Completed | — | — | — |
NCT00006383CT.gov Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00005634CT.gov Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | — | Completed | — | — | — |
NCT00577993CT.gov Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | — | Completed | — | — | — |
NCT00005867CT.gov Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00003215CT.gov Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00002565CT.gov Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01386398CT.gov Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT00324831CT.gov GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | — | Suspended | — | — | — |
NCT00517894CT.gov Dose-Dense Therapy in Aggressive Lymphoma | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | Beth Israel Deaconess Medical Center | Approved | BB · 70 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Bleomycin | Shandong Provincial Hospital | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Isocyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | P3 | BB |
+42 more in the Lymphoma cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (+)-Vincristine in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →